As reported by Kalo et al. [33] and more recently by Walerych et al. [34], in tumor cells affected by TP53 missense mutations, NRF2 cooperates with TP53 mutant isoforms and colocalizes on proteasome gene promoters, subsequently inhibiting multiple tumor suppressive pathways and driving an aggressive phenotype. This evidence concerns the gene TP53 and neoplasm.